Cardio Diagnostics Holdings, Inc. Ratios | P/E, ROE & Valuation

On the Key Ratios page for Cardio Diagnostics Holdings, Inc. (CDIO), the latest P/E of -0.6 frames valuation, while ROE -82.27% and ROIC -82.84% indicates profitability and capital efficiency. Together with the current ratio of 17.15 and debt-to-equity 0.05, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

CDIO Historical Per Share Metrics

6 years
Metric (FY)TTM20242023202220212020
Revenue per Share$0.00$0.00$0.04$0.00$0.00$0.00
Net Income per Share$-2.19$-0.31$-19.81$-1.51$-1.96$-0.06
Operating Cash Flow per Share$-1.91$-0.19$-13.41$-1.65$-1.85$0.00
Free Cash Flow per Share$-1.97$-0.19$-15.24$-1.67$-2.20$-0.00
Cash per Share$1.89$0.29$3.04$1.33$1.62$0.02
Book Value per Share$2.51$0.36$7.00$1.39$3.37$0.01
Tangible Book Value per Share$2.18$0.33$5.73$1.28$2.43$-0.01
Interest Debt per Share$0.13$0.04$18.91$0.27$0.00$0.00
CAPEX per Share$0.06$0.01$1.83$0.02$0.36$0.00

CDIO Historical Valuation Ratios

6 years
Metric (FY)TTM20242023202220212020
Price to Earnings (P/E)-0.63-88.25-3.77-21.07-150.59-4633.25
Price to Book (P/B)0.7377.4110.6822.8387.4846436.16
Price to Sales (P/S)376.8521204.541850.92103366.74103701.160
Enterprise Value to EBITDA-0.04-90.62-20.63-20.44-153.73-4687.09
EV to Sales15.8121007.991849.699926.22103132.050
EV to Operating Cash Flow-0.04-146.8-5.56-18.65-158.76108390.96
EV to Free Cash Flow-0.04-140.74-4.9-18.37-132.87-691898.77
Enterprise Value$228,424.00$732.97M$31.56M$94.93M$92.92M$2.80B

CDIO Historical Profitability Ratios

6 years
Metric (FY)TTM20242023202220212020
Return on Equity (ROE)-82.27%-87.71%-283.19%-108.35%-58.09%-1002.24%
Return on Invested Capital (ROIC)-82.84%-79.47%-171.65%-72.77%-58.09%-1008.86%
Return on Tangible Assets-93.02%-84.60%-213.39%-79.12%-77.22%-246.02%
Earnings Yield-118.81%-1.13%-26.52%-4.75%-0.66%-0.02%
Free Cash Flow Yield-107.27%-0.70%-20.41%-5.26%-0.75%-0.00%
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%

CDIO Historical Liquidity & Financial Strength

6 years
Metric (FY)TTM20242023202220212020
Current Ratio17.1513.923.296.9323.710.64
Interest Coverage-525.07-448.82-1.08000
Income Quality0.870.60.681.090.94-0.04
Debt to Equity0.050.10.430.200
Debt to Assets4.66%9.14%28.26%13.59%0.00%0.00%
Net Debt to EBITDA0.850.850.010.70.850.4

CDIO Historical Efficiency Ratios

6 years
Metric (FY)TTM20242023202220212020
Receivables Turnover3.71.873.44010
Payables Turnover0.733.150000
Inventory Turnover000000
Days Sales Outstanding98.64194.71106.0903650
Days Payables Outstanding501.63115.780000
Days of Inventory on Hand000000

CDIO Historical Market Metrics

6 years
Metric (FY)TTM20242023202220212020
Enterprise Value to EBITDA-0.04-90.62-20.63-20.44-153.73-4687.09
Market Cap$5.45M$739.83M$31.59M$98.20M$93.43M$2.80B
Enterprise Value$228,424.00$732.97M$31.56M$94.93M$92.92M$2.80B
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%
Payout Ratio0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

How does Cardio Diagnostics Holdings, Inc.’s P/E ratio compare with its history?

On this page, you can use the latest P/E (from the Key Ratios table) as your starting point and compare it to the company's multi-year P/E range in the historical rows. When the current P/E sits near its historical average, the multiple is close to that range. Look at trend direction in profitability and cash-flow rows, plus liquidity and leverage, rather than treating the P/E in isolation.

What is Cardio Diagnostics Holdings, Inc. market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $5.45M. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does Cardio Diagnostics Holdings, Inc.’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Cardio Diagnostics Holdings, Inc.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does Cardio Diagnostics Holdings, Inc. compare to its competitors in key financial ratios?

The fastest way to compare Cardio Diagnostics Holdings, Inc. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Cardio Diagnostics Holdings, Inc. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do Cardio Diagnostics Holdings, Inc.'s liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that Cardio Diagnostics Holdings, Inc. is financially strong. Current ratio is about 17.15, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about -525.07, implying less buffer for servicing interest costs. Debt-to-equity is about 0.05, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do Cardio Diagnostics Holdings, Inc.'s financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Cardio Diagnostics Holdings, Inc. is sustaining strong returns (for example ROE at -82.27% and ROIC at -82.84%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.